XORTX Therapeutics Inc.
4000, 421 7th Avenue SW
Calgary
Alberta
T2P 4K9
Canada
Tel: 1-403-455-7727
Website: http://www.xortx.com/
Email: info@xortx.com
About XORTX Therapeutics Inc.
XORTX Therapeutics Inc. is a BioPharmaceutical company focused on developing innovative therapies to treat progressive kidney disease. XORTX has lead programs to develop treatments for progressive kidney disease due to diabetes, diabetic nephropathy and polycystic kidney disease.
LEADERSHIP:
CEO: Allen Davidoff
CLINICAL TRIAL:
114 articles about XORTX Therapeutics Inc.
-
XORTX Submits a New Patent for the Treatment of Chronic Kidney Disease
1/3/2024
XORTX Therapeutics Inc., a late-stage clinical pharmaceutical company focused on developing innovative therapies to treat progressive kidney disease, announces submission of a new patent for the treatment of chronic kidney disease.
-
XORTX Welcomes New Member to the Board of Directors
1/2/2024
XORTX Therapeutics Inc. welcomes Mr. Patrick Treanor to the Board of Directors and announces the resignation of Ian Klassen, both effective December 31, 2023.
-
XORTX Meets Nasdaq Continued Listing Requirements - November 29, 2023
11/29/2023
XORTX Therapeutics Inc. announces that it has received a letter of compliance from the Nasdaq Stock Market LLC’s Listing Qualifications Department in connection with Nasdaq Rule 5550 that requires the shares to maintain a minimum bid price of US$1.00 per share.
-
XORTX Announces Share Consolidation
11/8/2023
XORTX Therapeutics Inc. announces that the Company’s board of directors has approved consolidating its common shares on the basis of one post-consolidation Share for every nine pre-consolidation Shares, effective November 9, 2023.
-
XORTX Sponsored Study Presented at the American Society of Nephrology – Kidney Week 2023
11/2/2023
XORTX Therapeutics Inc. is pleased to announce the presentation of new research findings at the American Society of Nephrology meeting being held November 3, 2023 in Philadelphia.
-
XORTX Announces Results of Special Meeting of Shareholders - October 27, 2023
10/27/2023
XORTX Therapeutics Inc., a late-stage clinical pharmaceutical company focused on developing innovative therapies to treat progressive kidney disease, announces the results of its special meeting of shareholders held earlier.
-
XORTX Announces Rescheduling of Special Meeting of Shareholders
10/25/2023
XORTX Therapeutics Inc. announces that the special meeting of shareholders that was scheduled for 10:00 a.m. (Calgary time) on October 25, 2023 (the “Meeting”) has been cancelled and will be rescheduled.
-
XORTX Announces Date for Rescheduled Special Meeting of Shareholders
10/25/2023
XORTX Therapeutics Inc. announces that further to its earlier press release, the special meeting of shareholders has been rescheduled to 10:00 a.m. on Friday, October 27, 2023.
-
XORTX Reports that Independent Proxy Firm, ISS, Recommends Shareholders Vote for the Share Consolidation Resolution
10/12/2023
ISS, a leading proxy advisory firm, recommends XORTX Therapeutics Inc.’s shareholders vote FOR the share consolidation resolution, stating that approving the share consolidation will “enhance the long-term growth prospects of the Company by broadening its financing alternatives.”
-
XORTX Calls Special Meeting of Shareholders
10/4/2023
XORTX Therapeutics Inc., a late-stage clinical pharmaceutical company focused on developing innovative therapies to treat progressive kidney disease, announces that the Company has called a special meeting of shareholders for 10:00 a.m. on October 25, 2023.
-
XORTX Sponsored Study Selected for Presentation at the American Society of Nephrology – Kidney Week 2023
9/28/2023
XORTX Therapeutics Inc., a late-stage clinical pharmaceutical company focused on developing innovative therapies to treat progressive kidney disease, is pleased to announce the acceptance of an abstract submitted to the American Society of Nephrology.
-
XORTX Announces Participation at Upcoming Investor Conferences - September 11, 2023
9/11/2023
XORTX Therapeutics Inc., a late-stage clinical pharmaceutical company focused on developing innovative therapies to treat progressive kidney disease, announces that Dr. Allen Davidoff, President and CEO, is scheduled to participate in the following upcoming investor conferences.
-
XORTX Submits Orphan Drug Designation Application to the European Medicines Agency (EMA) to Treat Progressive Kidney Disease
8/29/2023
XORTX Therapeutics Inc. (“XORTX” or the “Company”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a late-stage clinical pharmaceutical company focused on developing innovative therapies to treat progressive kidney disease, announces that it has submitted an Orphan Drug Designation application for XORLO™ to the European Medicines Agency (the “EMA”).
-
XORTX Appoints Chief Financial Officer
8/4/2023
XORTX Therapeutics Inc., a late-stage clinical pharmaceutical company focused on developing innovative therapies to treat progressive kidney disease, is pleased to announce the appointment of James Fairbairn as Chief Financial Officer to replace Amar Keshri who left the Company’s employ effective July 31, 2023.
-
XORTX Announces Results of Annual and Special Meeting of Shareholders
6/29/2023
XORTX Therapeutics Inc. is pleased to announce the results of its annual and special meeting of shareholders (the “Meeting”) held Wednesday, June 28, 2023.
-
XORTX Reminds Shareholders to Vote ahead of the Proxy Voting Deadline for the Company’s Upcoming Annual and Special Meeting of Shareholders
6/24/2023
XORTX Therapeutics Inc. would like to remind shareholders that they have until 10:00 a.m. on Monday, June 26, 2023 to vote their shares for the Company’s upcoming annual and special meeting of shareholders to be held on Wednesday, June 28, 2023 at 10:00 a.m.
-
XORTX Announces PKD Presentation
6/6/2023
XORTX Therapeutics Inc. is pleased to announce presentation of scientific data underpinning the recent Orphan Drug Designation (“ ODD ”) at the PKD Foundation – “PKD Connect” meeting being held June 22-24, 2023 in Denver, Colorado.
-
FDA Confirms Eligibility of XORLO™ for Accelerated Approval
5/4/2023
XORTX Therapeutics Inc. is pleased to announce completion of a positive and constructive Type D meeting with the U.S. Food and Drug Administration (“FDA”) which resulted in the identification of additional clinical endpoints potentially available for accelerated approval and further understanding of the FDA expectations for the accelerated approval of XORLO™ for the treatment of autosomal dominant polycystic kidney disease (“ADPKD”).
-
XORTX Announces Receipt of FDA Orphan Drug Designation to Treat Autosomal Dominant Kidney Disease
4/21/2023
XORTX Therapeutics Inc. is pleased to announce the grant of Orphan Drug Designation for oxypurinol – “orphan-drug designation request of oxypurinol is granted for treatment of autosomal dominant polycystic kidney disease”.
-
XORTX Announces Type D Meeting with FDA to be held May 1, 2023
3/14/2023
XORTX Therapeutics Inc. is pleased to announce submission of a Type D meeting request to the US Food and Drug Administration (“FDA”).